Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 2/20 | 0.51 |
| ▸ | WNT1 | P04628 | 3/20 | 0.47 |
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 13/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320781 | 1.00 | WNT3A (0.51) | WNT3AWNT1GSK3BDYRK1ANPY5R | |
| SCHEMBL2418827 | 1.00 | WNT3A (0.51) | WNT3AWNT1GSK3BDYRK1ANPY5R | |
| SCHEMBL2316827 | 0.83 | WNT3A (0.58) | WNT3AGSK3BDYRK1ANPY5RABCB1 | |
| SCHEMBL2318727 | 0.81 | POLB (0.57) | WNT1GSK3BDYRK1A | |
| SCHEMBL2417106 | 0.81 | POLB (0.57) | WNT1GSK3BDYRK1A | |
| SCHEMBL2418857 | 0.81 | POLB (0.57) | WNT1GSK3BDYRK1A | |
| SCHEMBL2320233 | 0.80 | NPY5R (0.47) | WNT3AGSK3BDYRK1ANPY5RABCB1 | |
| SCHEMBL2415738 | 0.80 | NPY5R (0.47) | WNT3AGSK3BDYRK1ANPY5RABCB1 | |
| SCHEMBL2322128 | 0.80 | NPY5R (0.47) | WNT3AGSK3BDYRK1ANPY5RABCB1 | |
| SCHEMBL2359496 | 0.80 | WNT3A (0.54) | WNT3AWNT1GSK3BDYRK1ANPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| EP-2352730-A2 | BIOLOGICALLY ACTIVE AMIDES | H. Lundbeck A/S (DK) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010053861-A2 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | NPY5R, NPY1R, NPY2R | WNT3A 4719/4885WNT1 4752/4885GSK3B 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.